Sharemaestro Newsreel

Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as KDIGO Endorsement Expands Market Opportunity

Talphera Inc. (TLPH) announced significant progress in its Q2 2026 earnings call, with 75% enrollment in its NEPHRO CRRT study and the 2026 KDIGO guidelines now referencing nafamostat as an acceptable regional anticoagulant. The company also reported a cash balance of $17.1 million and …

What Could Eton Pharmaceuticals (ETON) Gain From The ASN 001 Licensing Deal?

Gabriele Ricci Sells 25,088 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock

Takeda Pharmaceutical (NYSE:TAK) Insider Sells $392,564.70 in Stock

Agosti Marcello Pignagnoli, an insider at Takeda Pharmaceutical (NYSE:TAK), sold 22,957 shares worth $392,564.70 to cover tax obligations from vested equity awards, reducing his direct ownership by 11.48%. The company's shares are trading at $17.42 with a market cap of $55.82 billion, and analysts …

Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $124,436.70 in Stock

Ramy Riad Ahmed Ibrahim, an insider at Takeda Pharmaceutical (NYSE:TAK), sold 7,277 shares of company stock worth $124,436.70. This transaction, which reduced his ownership by 6.62%, was primarily to cover tax obligations related to vested equity awards. The company's stock is currently trading near …

Takeda Pharmaceutical (NYSE:TAK) CEO Sells $1,523,439.00 in Stock

Takeda Pharmaceutical's CEO, Julie So-Young Kim, sold 89,090 shares of company stock for over $1.5 million to cover tax obligations from vested equity awards, reducing her ownership by 18.54%. The company's stock trades at $17.42 with a market cap of $55.82 billion, and analyst …

Elaine Mary Shannon Sells 3,978 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical (NYSE: TAK) executive sells 7,277 ADS in tax-related trade

Ramy Riad Ahmed, President of the PDT business unit at Takeda Pharmaceutical Co Ltd (NYSE: TAK), sold 7,277 American Depositary Shares (ADS) on August 10, 2026, at a weighted average price of $17.10 per share. This sale was mandatory to cover taxes related to …

Takeda (TAK) executive sells 25,088 ADSs in mandatory tax-related trade

Takeda Pharmaceutical Co Ltd's Chief Data & Tech. Officer, Gabriele Ricci, sold 25,088 American Depositary Shares (ADSs) on August 10, 2026, at a weighted average price of $17.10 per ADS. This transaction was a mandatory sale to cover tax obligations related to vested equity …

Amphastar director Richard Prins disposes of shares valued at $161,851

Amphastar Pharmaceuticals director Richard K. Prins sold 7,973 shares of the company's common stock for $161,851. This transaction occurred on August 11, 2026, with shares priced at $20.3 each, leaving him with 29,625 shares. The sale follows the company's strong Q2 2026 revenue of …

Takeda Pharmaceutical (NYSE: TAK) counsel sells 30,868 ADSs to cover taxes

Takeda Pharmaceutical's Global General Counsel, Natalie Anne Marie Furney, sold 30,868 American Depositary Shares (ADSs) on August 10, 2026, for a weighted average price of $17.10 per ADS. This transaction was a mandatory sale to cover tax obligations related to the vesting of equity …

United Therapeutics Corp (UTHR) CEO’s trust sells 9,500 shares under 10b5-1 plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), had a family trust execute and sell 9,500 shares. This transaction, conducted on August 12, 2026, was part of a pre-arranged Rule 10b5-1 trading plan. The trust exercised 9,500 stock options at $135.42 …

Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission

Aquestive Therapeutics (AQST) stock experienced a 4% dip despite positive Q2 results showing increased liquidity and reaffirmed revenue guidance. The company is nearing resubmission of its Anaphylm New Drug Application, with management addressing FDA concerns. However, ongoing adjusted EBITDA losses and the dependence on …

Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Richard Prins, a director at Amphastar Pharmaceuticals (NASDAQ:AMPH), sold 7,973 shares of the company's stock for over $161,000, reducing his direct holdings by more than 21%. Despite the sale and a "Reduce" consensus rating from analysts, the company recently reported strong quarterly earnings, beating …

BETA Technologies Inc (BETA) (Q2 2026) Earnings Call Highlights: Revenue Surges 146% as ...

This article first appeared on GuruFocus. Release Date: August 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenue in Q2 2026 was $14.7 million, exceeding guidance and up 146% year-over-year, driven by …

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 5 p.m. ET CALL PARTICIPANTS Vice President and Treasurer - Frank VargoPresident and Chief Executive Officer - Joseph C. Papa Jr.Executive Vice President and Chief Financial Officer - Richard S. Lindahl TAKEAWAYS Total …

Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A

Tushar Patel has filed an Amendment No. 6 to his Schedule 13D, disclosing beneficial ownership of 61,341,678 shares of Amneal Pharmaceuticals Class A common stock, representing 17.6% of the outstanding shares. This updated ownership stake reflects shares acquired through the recent Kashiv BioSciences acquisition, …

Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares

Amneal Pharmaceuticals, Inc. has completed its acquisition of Kashiv BioSciences, LLC for $375 million in cash and 28,942,098 shares of Class A Common Stock. This transaction has resulted in Chintu Patel becoming the beneficial owner of 32,576,528 shares, representing 9.4% of Amneal's Class A …

Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.1% - Time to Sell?

Tilray Brands (NASDAQ:TLRY) saw its share price drop by 2.1% to $4.68, with trading volume significantly below average. Despite a consensus "Moderate Buy" rating from analysts with an $11.00 price target, the company recently missed EPS expectations, reporting a loss of $0.43 against an …

Can Organigram (TSX:OGI) Cannabis Stocks Capture Greater Share?

Organigram Holdings (TSX:OGI) is strategically positioning itself in the competitive Canadian cannabis market through brand diversification across premium, mainstream, and value segments, and product innovation to include vapes and edibles. The company also uses strategic consolidation to achieve greater scale and operational efficiency, aiming …

Earnings call transcript: Talphera Q2 2026 meets estimates as stock slips

Talphera Inc. reported a Q2 2026 loss of negative $0.06 per share, matching Wall Street estimates, but its stock declined. The company is advancing its nafamostat program for continuous renal replacement therapy (CRRT), with its NEPHRO-CRRT trial 75% enrolled and a potential market for …

Liquidia (LQDA) Turns Profitable In Q2, Is The Pullback A Valuation Opportunity?

Liquidia (LQDA) recently reported Q2 2026 results, shifting to profitability with increased revenue and positive net income, despite a recent share price pullback of over 10%. The company's stock has shown strong long-term performance, with a 212.66% return over the past year. Analysts see …

Elanco Animal Health expands US screwworm response

Elanco Animal Health president and CEO Jeff Simmons discusses the company's efforts to combat the screwworm outbreak in the United States. The discussion took place on 'The Claman Countdown', highlighting Elanco's expanded response to the health issue.

United Therapeutics Corp (UTHR) CEO trades 9,500 shares after option exercise

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 common shares between $512.94 and $531.29 per share on August 11, 2026. This transaction was conducted under a …

Viatris Inc. stock falls Wednesday, underperforms market

Viatris Inc. (VTRS) shares fell by 1.11% on Wednesday, closing at $16.10, underperforming the broader market. The S&P 500 Index saw a gain of 0.26%, while the Dow Jones Industrial Average slightly declined by 0.04%. Viatris Inc. is now trading 12.45% below its 52-week …

Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal

Amneal Pharmaceuticals director Gautam Patel reported an indirect acquisition of 283,632 Class A common shares on August 10, 2026. These shares were received by limited liability companies he manages as part of Amneal's acquisition of Kashiv BioSciences, LLC. Following this transaction, Patel directly holds …

Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal

Amneal Pharmaceuticals' Co-CEO, Chirag K. Patel, through entities he manages, acquired 6,381,734 Class A common shares on August 10, 2026. This share issuance was part of Amneal's acquisition of Kashiv BioSciences, LLC. After the transaction, Patel holds 1,393,470 shares directly and 21,269,420 shares indirectly …

Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares

Xeris Biopharma insider Steven Pieper has filed to sell 20,000 common shares under Rule 144, with an aggregate market value of $167,800.00, to be handled by Morgan Stanley Smith Barney LLC. These shares originated from Restricted Stock Units granted in January 2025. This planned …

Hims & Hers shared patient health data with Meta, Snap and other advertisers, new class action lawsuit claims

A new class action lawsuit has been filed against Hims & Hers Health Inc., alleging that the telehealth company secretly shared sensitive patient health data and identifying details with advertising and analytics firms like Meta, Google, and Snap without consent. The lawsuit claims that …

Needham & Company LLC Issues Positive Forecast for Liquidia (NASDAQ:LQDA) Stock Price

Needham & Company LLC has raised its price target for Liquidia (NASDAQ:LQDA) to $110 from $70, maintaining a "buy" rating and implying a 39% upside. Despite strong Q2 2026 revenue of $171.7 million and net income of $74.7 million, the stock fell 10.2% after …

What’s Next For Cardiol Therapeutics (TSX:CRDL) Research?

Cardiol Therapeutics (TSX:CRDL) is a clinical-stage life sciences company focused on developing therapies for cardiovascular conditions, with its research strategy centered on addressing unmet therapeutic needs in this area. The company's future hinges on clinical execution, regulatory developments, and the quality of its trial …

Talphera (TLPH): Rosalind entities report 9.9% beneficial ownership cap

Rosalind Master Fund L.P. and related entities have reported a 9.9% beneficial ownership in Talphera, Inc. (TLPH) through a Schedule 13G/A filing. The filing indicates beneficial ownership of 5,169,501 common shares, representing approximately 9.96% of Talphera's outstanding stock. This percentage is capped due to …

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

Neurocrine Biosciences (NBIX) stock is down 3.1% today, likely due to investor profit-taking and a reset of expectations following its late-July earnings release. While the company reported strong revenue growth and increased INGREZZA sales guidance, it also raised spending outlooks and highlighted the balance-sheet …

Kamada (NASDAQ:KMDA) Issues Earnings Results

Aquestive Therapeutics Releases Q2 2026 Financial Results

Aquestive Therapeutics (AQST) reported a Q2 2026 diluted loss per share of $0.18, exceeding the expected loss of $0.11, with total revenue reaching $13.8 million, a 38.0% increase year-over-year. The company's net loss for the quarter was $22.9 million, and it ended with $98.5 …